API5 induces cisplatin resistance through FGFR signaling in human cancer cells

Han Sol Jang, Seon Rang Woo, Kwon Ho Song, Hanbyoul Cho, Doo Byung Chay, Soon Oh Hong, Hyo Jung Lee, Se Jin Oh, Joon Yong Chung, Jae-Hoon Kim, Tae Woo Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Most tumors frequently undergo initial treatment with a chemotherapeutic agent but ultimately develop resistance, which limits the success of chemotherapies. As cisplatin exerts a high therapeutic effect in a variety of cancer types, it is often used in diverse strategies, such as neoadjuvant, adjuvant and combination chemotherapies. However, cisplatin resistance has often manifested regardless of cancer type, and it represents an unmet clinical need. Since we found that API5 expression was positively correlated with chemotherapy resistance in several specimens from patients with cervical cancer, we decided to investigate whether API5 is involved in the development of resistance after chemotherapy and to explore whether targeting API5 or its downstream effectors can reverse chemo-resistance. For this purpose, cisplatin-resistant cells (CaSki P3 CR) were established using three rounds of in vivo selection with cisplatin in a xenografted mouse. In the CaSki P3 CR cells, we observed that API5 acted as a chemo-resistant factor by rendering cancer cells resistant to cisplatin-induced apoptosis. Mechanistic investigations revealed that API5 mediated chemo-resistance by activating FGFR1 signaling, which led to Bim degradation. Importantly, FGFR1 inhibition using either an siRNA or a specific inhibitor disrupted cisplatin resistance in various types of API5high cancer cells in an in vitro cell culture system as well as in an in vivo xenograft model. Thus, our results demonstrated that API5 promotes chemo-resistance and that targeting either API5 or its downstream FGFR1 effectors can sensitize chemo-refractory cancers.

Original languageEnglish
Pages (from-to)e374
JournalExperimental & molecular medicine
Volume49
Issue number9
DOIs
Publication statusPublished - 2017 Sep 8

Fingerprint

Cisplatin
Chemotherapy
Cells
Neoplasms
Drug Therapy
Therapeutic Uses
Adjuvant Chemotherapy
Combination Drug Therapy
Cell culture
Heterografts
Uterine Cervical Neoplasms
Refractory materials
Small Interfering RNA
Tumors
Cell Culture Techniques
Apoptosis
Degradation

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Jang, H. S., Woo, S. R., Song, K. H., Cho, H., Chay, D. B., Hong, S. O., ... Kim, T. W. (2017). API5 induces cisplatin resistance through FGFR signaling in human cancer cells. Experimental & molecular medicine, 49(9), e374. https://doi.org/10.1038/emm.2017.130
Jang, Han Sol ; Woo, Seon Rang ; Song, Kwon Ho ; Cho, Hanbyoul ; Chay, Doo Byung ; Hong, Soon Oh ; Lee, Hyo Jung ; Oh, Se Jin ; Chung, Joon Yong ; Kim, Jae-Hoon ; Kim, Tae Woo. / API5 induces cisplatin resistance through FGFR signaling in human cancer cells. In: Experimental & molecular medicine. 2017 ; Vol. 49, No. 9. pp. e374.
@article{d39ca6da8c674f50aa37e88769124c58,
title = "API5 induces cisplatin resistance through FGFR signaling in human cancer cells",
abstract = "Most tumors frequently undergo initial treatment with a chemotherapeutic agent but ultimately develop resistance, which limits the success of chemotherapies. As cisplatin exerts a high therapeutic effect in a variety of cancer types, it is often used in diverse strategies, such as neoadjuvant, adjuvant and combination chemotherapies. However, cisplatin resistance has often manifested regardless of cancer type, and it represents an unmet clinical need. Since we found that API5 expression was positively correlated with chemotherapy resistance in several specimens from patients with cervical cancer, we decided to investigate whether API5 is involved in the development of resistance after chemotherapy and to explore whether targeting API5 or its downstream effectors can reverse chemo-resistance. For this purpose, cisplatin-resistant cells (CaSki P3 CR) were established using three rounds of in vivo selection with cisplatin in a xenografted mouse. In the CaSki P3 CR cells, we observed that API5 acted as a chemo-resistant factor by rendering cancer cells resistant to cisplatin-induced apoptosis. Mechanistic investigations revealed that API5 mediated chemo-resistance by activating FGFR1 signaling, which led to Bim degradation. Importantly, FGFR1 inhibition using either an siRNA or a specific inhibitor disrupted cisplatin resistance in various types of API5high cancer cells in an in vitro cell culture system as well as in an in vivo xenograft model. Thus, our results demonstrated that API5 promotes chemo-resistance and that targeting either API5 or its downstream FGFR1 effectors can sensitize chemo-refractory cancers.",
author = "Jang, {Han Sol} and Woo, {Seon Rang} and Song, {Kwon Ho} and Hanbyoul Cho and Chay, {Doo Byung} and Hong, {Soon Oh} and Lee, {Hyo Jung} and Oh, {Se Jin} and Chung, {Joon Yong} and Jae-Hoon Kim and Kim, {Tae Woo}",
year = "2017",
month = "9",
day = "8",
doi = "10.1038/emm.2017.130",
language = "English",
volume = "49",
pages = "e374",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "9",

}

Jang, HS, Woo, SR, Song, KH, Cho, H, Chay, DB, Hong, SO, Lee, HJ, Oh, SJ, Chung, JY, Kim, J-H & Kim, TW 2017, 'API5 induces cisplatin resistance through FGFR signaling in human cancer cells', Experimental & molecular medicine, vol. 49, no. 9, pp. e374. https://doi.org/10.1038/emm.2017.130

API5 induces cisplatin resistance through FGFR signaling in human cancer cells. / Jang, Han Sol; Woo, Seon Rang; Song, Kwon Ho; Cho, Hanbyoul; Chay, Doo Byung; Hong, Soon Oh; Lee, Hyo Jung; Oh, Se Jin; Chung, Joon Yong; Kim, Jae-Hoon; Kim, Tae Woo.

In: Experimental & molecular medicine, Vol. 49, No. 9, 08.09.2017, p. e374.

Research output: Contribution to journalArticle

TY - JOUR

T1 - API5 induces cisplatin resistance through FGFR signaling in human cancer cells

AU - Jang, Han Sol

AU - Woo, Seon Rang

AU - Song, Kwon Ho

AU - Cho, Hanbyoul

AU - Chay, Doo Byung

AU - Hong, Soon Oh

AU - Lee, Hyo Jung

AU - Oh, Se Jin

AU - Chung, Joon Yong

AU - Kim, Jae-Hoon

AU - Kim, Tae Woo

PY - 2017/9/8

Y1 - 2017/9/8

N2 - Most tumors frequently undergo initial treatment with a chemotherapeutic agent but ultimately develop resistance, which limits the success of chemotherapies. As cisplatin exerts a high therapeutic effect in a variety of cancer types, it is often used in diverse strategies, such as neoadjuvant, adjuvant and combination chemotherapies. However, cisplatin resistance has often manifested regardless of cancer type, and it represents an unmet clinical need. Since we found that API5 expression was positively correlated with chemotherapy resistance in several specimens from patients with cervical cancer, we decided to investigate whether API5 is involved in the development of resistance after chemotherapy and to explore whether targeting API5 or its downstream effectors can reverse chemo-resistance. For this purpose, cisplatin-resistant cells (CaSki P3 CR) were established using three rounds of in vivo selection with cisplatin in a xenografted mouse. In the CaSki P3 CR cells, we observed that API5 acted as a chemo-resistant factor by rendering cancer cells resistant to cisplatin-induced apoptosis. Mechanistic investigations revealed that API5 mediated chemo-resistance by activating FGFR1 signaling, which led to Bim degradation. Importantly, FGFR1 inhibition using either an siRNA or a specific inhibitor disrupted cisplatin resistance in various types of API5high cancer cells in an in vitro cell culture system as well as in an in vivo xenograft model. Thus, our results demonstrated that API5 promotes chemo-resistance and that targeting either API5 or its downstream FGFR1 effectors can sensitize chemo-refractory cancers.

AB - Most tumors frequently undergo initial treatment with a chemotherapeutic agent but ultimately develop resistance, which limits the success of chemotherapies. As cisplatin exerts a high therapeutic effect in a variety of cancer types, it is often used in diverse strategies, such as neoadjuvant, adjuvant and combination chemotherapies. However, cisplatin resistance has often manifested regardless of cancer type, and it represents an unmet clinical need. Since we found that API5 expression was positively correlated with chemotherapy resistance in several specimens from patients with cervical cancer, we decided to investigate whether API5 is involved in the development of resistance after chemotherapy and to explore whether targeting API5 or its downstream effectors can reverse chemo-resistance. For this purpose, cisplatin-resistant cells (CaSki P3 CR) were established using three rounds of in vivo selection with cisplatin in a xenografted mouse. In the CaSki P3 CR cells, we observed that API5 acted as a chemo-resistant factor by rendering cancer cells resistant to cisplatin-induced apoptosis. Mechanistic investigations revealed that API5 mediated chemo-resistance by activating FGFR1 signaling, which led to Bim degradation. Importantly, FGFR1 inhibition using either an siRNA or a specific inhibitor disrupted cisplatin resistance in various types of API5high cancer cells in an in vitro cell culture system as well as in an in vivo xenograft model. Thus, our results demonstrated that API5 promotes chemo-resistance and that targeting either API5 or its downstream FGFR1 effectors can sensitize chemo-refractory cancers.

UR - http://www.scopus.com/inward/record.url?scp=85047201599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047201599&partnerID=8YFLogxK

U2 - 10.1038/emm.2017.130

DO - 10.1038/emm.2017.130

M3 - Article

VL - 49

SP - e374

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 9

ER -